GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » EV-to-EBITDA

Lee's Pharmaceutical Holdings (STU:L1PA) EV-to-EBITDA : 9.53 (As of Jan. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lee's Pharmaceutical Holdings's enterprise value is €87.5 Mil. Lee's Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €9.2 Mil. Therefore, Lee's Pharmaceutical Holdings's EV-to-EBITDA for today is 9.53.

The historical rank and industry rank for Lee's Pharmaceutical Holdings's EV-to-EBITDA or its related term are showing as below:

STU:L1PA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.34   Med: 9.22   Max: 31.28
Current: 9.07

During the past 13 years, the highest EV-to-EBITDA of Lee's Pharmaceutical Holdings was 31.28. The lowest was 0.34. And the median was 9.22.

STU:L1PA's EV-to-EBITDA is ranked better than
70.75% of 718 companies
in the Drug Manufacturers industry
Industry Median: 13.655 vs STU:L1PA: 9.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-01-18), Lee's Pharmaceutical Holdings's stock price is €0.149. Lee's Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.013. Therefore, Lee's Pharmaceutical Holdings's PE Ratio (TTM) for today is 11.46.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Lee's Pharmaceutical Holdings EV-to-EBITDA Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings EV-to-EBITDA Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.75 9.33 0.89 3.76 4.47

Lee's Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.74 3.76 40.75 4.47 -

Competitive Comparison of Lee's Pharmaceutical Holdings's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's EV-to-EBITDA falls into.



Lee's Pharmaceutical Holdings EV-to-EBITDA Calculation

Lee's Pharmaceutical Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=87.484/9.184
=9.53

Lee's Pharmaceutical Holdings's current Enterprise Value is €87.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €9.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (STU:L1PA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Lee's Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.149/0.013
=11.46

Lee's Pharmaceutical Holdings's share price for today is €0.149.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.013.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Lee's Pharmaceutical Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines